Loading...
At this year's meeting of the American Society of Clinical Oncology, held virtually June 4–8, 2021, investigators discussed the latest findings in cancer research. Associate Editor Robert Dreicer, MD, MS, MACP, FASCO, reviewed key presentations on new genitourinary cancer therapies. Meeting abstracts can be viewed in the ASCO meeting library.
Prostate-specific membrane antigen (PSMA) is a transmembrane molecule expressed in greater than 85% of men with advanced prostate cancer. Lutetium-labeled PSMA 617 (177Lu-PSMA-617) is a radiolabeled small molecule that binds to PSMA.
Investigators conducted an industry-sponsored phase III trial of 177Lu-PSM…